This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hepatitis B
and you are
between 20 and 35
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.

Provided treatments

  • Biological: 2XP HEPTAVAX™-II SC
  • Biological: 1XP HEPTAVAX™-II SC
  • Biological: 2XP HEPTAVAX™-II IM

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01463683. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 722 volunteers for the current phase.
Official trial title:
A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process